DDInter150 DDInter1824
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.
Azathioprine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Tioguanine
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Tocilizumab
Azathioprine {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Azathioprine {u} (Compound) treats {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tocilizumab
Azathioprine {u} (Compound) treats {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is palliated by {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Tioguanine
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Azathioprine {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tocilizumab
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is downregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Azathioprine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is downregulated by {v} (Compound) Pitavastatin
Pitavastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Azathioprine {u} (Compound) upregulates {v} (Gene) NUCB2
NUCB2 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tocilizumab
Azathioprine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Tioguanine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Azathioprine (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Tocilizumab
Azathioprine (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Methotrexate (Compound) and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Azathioprine (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Tocilizumab
Azathioprine (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Tioguanine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Azathioprine (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is downregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Azathioprine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is downregulated by Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Azathioprine (Compound) upregulates NUCB2 (Gene) and NUCB2 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab